- Home
- HL vs PTGX Comparison
HL vs PTGX Comparison
Compare HL & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HL
- PTGX
- Stock Information
- Founded
- HL 1891
- PTGX 2006
- Country
- HL United States
- PTGX United States
- Employees
- HL N/A
- PTGX N/A
- Industry
- HL Precious Metals
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- HL Basic Materials
- PTGX Health Care
- Exchange
- HL Nasdaq
- PTGX Nasdaq
- Market Cap
- HL 3.9B
- PTGX 3.7B
- IPO Year
- HL N/A
- PTGX 2016
- Fundamental
- Price
- HL $9.02
- PTGX $60.09
- Analyst Decision
- HL Hold
- PTGX Strong Buy
- Analyst Count
- HL 5
- PTGX 8
- Target Price
- HL $7.60
- PTGX $70.13
- AVG Volume (30 Days)
- HL 22.8M
- PTGX 696.8K
- Earning Date
- HL 08-06-2025
- PTGX 08-06-2025
- Dividend Yield
- HL 0.17%
- PTGX N/A
- EPS Growth
- HL N/A
- PTGX N/A
- EPS
- HL 0.16
- PTGX 0.80
- Revenue
- HL $1,060,106,000.00
- PTGX $209,180,000.00
- Revenue This Year
- HL $12.80
- PTGX N/A
- Revenue Next Year
- HL $2.00
- PTGX $185.11
- P/E Ratio
- HL $55.92
- PTGX $72.23
- Revenue Growth
- HL 36.30
- PTGX N/A
- 52 Week Low
- HL $4.46
- PTGX $33.31
- 52 Week High
- HL $9.08
- PTGX $61.89
- Technical
- Relative Strength Index (RSI)
- HL 79.59
- PTGX 62.87
- Support Level
- HL $8.75
- PTGX $57.45
- Resistance Level
- HL $9.08
- PTGX $60.71
- Average True Range (ATR)
- HL 0.29
- PTGX 2.23
- MACD
- HL 0.08
- PTGX 0.25
- Stochastic Oscillator
- HL 96.81
- PTGX 79.13
About HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.